Business
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPT
About this update from Fibrobiologics, Inc.
[{"type":"image","alt":"FibroBiologics, Inc.","displaySize":"","headline":null,"caption":"FibroBiologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xw_QEbMhw7ViThavcOHCOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425","width":300,"height":77}},"lazy":false},{"type":"text","content":"Platform Poised to Expand into Joint and Cartilage Repair","length":57,"tagName":"p"},{"type":"text","content":"HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has submitted a new patent application with the U.S. Patent and Trademark Office (USPTO) titled “Spheroids For Cartilage Repair” covering a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration.","length":675,"tagName":"p"},{"type":"text","content":"The application, if granted, strengthens the protection for the Company’s novel fibroblast technology that leverages fibroblast cells, spheroids, and/or fibroblast-differentiated chondrocyte spheroids to support structural and functional repair in orthopedic tissues. Preclinical studies demonstrate that fibroblast-based constructs and chondrocyte spheroids integrate with native tissue, promote extracellular matrix remodeling, and encourage regeneration in models of disc degeneration and joint degeneration.","length":511,"tagName":"p"},{"type":"text","content":"“This patent application represents an important step forward in expanding our vision of advancing fibroblast-based therapies from chronic wounds and immunology into the structural repair of the entire musculoskeletal system. If granted, this patent would provide broad protection for multiple therapeutic indications across orthopedics, positioning FibroBiologics to address large, underserved markets in degenerative disc diseas...